# A Study With CIT-013 in RA Patients

> **NCT06567470** · PHASE2 · RECRUITING · sponsor: **Citryll BV** · enrollment: 88 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** CIT-013 low dose
- **DRUG:** CIT-013 high dose
- **DRUG:** Placebo
- **DRUG:** CIT-013 medium dose

## Key facts

- **NCT ID:** NCT06567470
- **Lead sponsor:** Citryll BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-29
- **Primary completion:** 2027-04
- **Final completion:** 2027-07
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567470, "A Study With CIT-013 in RA Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06567470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*